Form 8-K - Current report:
SEC Accession No. 0001641172-25-017906
Filing Date
2025-07-07
Accepted
2025-07-07 06:04:08
Documents
19
Period of Report
2025-07-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 57791
2 EX-2.1 ex2-1.htm EX-2.1 36746
3 EX-99.1 ex99-1.htm EX-99.1 27549
4 GRAPHIC form8-k_001.jpg GRAPHIC 5590
5 GRAPHIC ex99-1_001.jpg GRAPHIC 3427
6 GRAPHIC ex99-1_002.jpg GRAPHIC 2226
  Complete submission text file 0001641172-25-017906.txt   374796

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE cycc-20250707.xsd EX-101.SCH 3743
8 XBRL DEFINITION FILE cycc-20250707_def.xml EX-101.DEF 26581
9 XBRL LABEL FILE cycc-20250707_lab.xml EX-101.LAB 36613
10 XBRL PRESENTATION FILE cycc-20250707_pre.xml EX-101.PRE 25205
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5747
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 251106907
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)